Cytek Biosciences, Inc.
CTKB Nasdaq
SEC CIK 1831915
Follow Cytek Biosciences
Weekly email: filings, results
Revenue, last quarter
$53.2M
+1.8% vs same quarter last year
Net income
−$6.1M
−11.3% vs same quarter last year
EPS, diluted
-
Operating cash flow
−$4.5M
−14.2% vs same quarter last year
Source: SEC XBRL filings · latest filing
- Revenue
- Net income
Show the numbers
| Year | Revenue | Net income |
|---|---|---|
| FY25 | $201.5M | −$66.5M |
| FY24 | $200.5M | −$6M |
| FY23 | $193M | −$12.1M |
| FY22 | $164M | $2.5M |
| FY21 | $128M | $3M |
| FY20 | $92.8M | $19.4M |
| FY19 | - | - |
- Gross margin
- Operating margin
- Net margin
Show the numbers
| Year | Gross margin | Operating margin | Net margin |
|---|---|---|---|
| FY25 | 51.8% | −20% | −33% |
| FY24 | 55.4% | −10.2% | −3% |
| FY23 | 56.7% | −14.4% | −6.3% |
| FY22 | 61.6% | −1.1% | 1.5% |
| FY21 | 61.9% | 7.2% | 2.4% |
| FY20 | 55.7% | 14.7% | 20.9% |
| FY19 | - | - | - |
Show the numbers
| Year | Free cash flow |
|---|---|
| FY25 | −$8.8M |
| FY24 | $21.9M |
| FY23 | $633K |
| FY22 | −$22M |
| FY21 | $266K |
| FY20 | $13.6M |
| FY19 | - |
Show the numbers
| Year | Buybacks |
|---|---|
| FY25 | $15.1M |
| FY24 | $21.6M |
| FY23 | $44.2M |
| FY22 | $0 |
| FY21 | $0 |
| FY20 | - |
| FY19 | - |
- Cytek Biosciences
- Technology median
Show the numbers
| Year | Cytek Biosciences | Technology median |
|---|---|---|
| FY25 | −33% | −2.4% |
| FY24 | −3% | −5% |
| FY23 | −6.3% | −6.7% |
| FY22 | 1.5% | −4.4% |
| FY21 | 2.4% | −1.7% |
| FY20 | 20.9% | −3% |
| FY19 | - | 0% |